CD19 and neoplasm: Approximately 70% of patients showed complete or at least partial response to treatment with autologous T cells equipped with CD19-specific CARs.1, 2, 3, 4 CARs are synthetic receptors that retarget genetically engineered T cells against tumor surface antigens.